Ashurst advised a pool of unitranche lenders on the financing of the acquisition of Olyos (formerly EA Pharma), a leading player in the natural health sector, held by Motion Equity Partners. This transaction is part of the raising of a continuation fund by Motion Equity Partners, aimed at supporting the next phase of Olyos's growth.
Olyos, a recognized specialist in dietary supplements and natural health, enjoys strong brand recognition thanks to its flagship brands and its commitment to innovation and quality. The investment by Motion Equity Partners, through this continuation fund, will enable Olyos to accelerate its development, notably by expanding its product range and strengthening its international presence.
The Ashurst team was led by Pierre Roux (partner), assisted by Kevin Perraudin (senior associate), Annissa Baghafor (associate), and Milan Czjaka (junior associate) in banking and finance; François Hellot (partner), Elsa Decourt (counsel), Gaspard Bastien-Thiry (counsel), Astrid Hubert-Benoist (associate), and Athénaïs de Sercey (associate) in corporate; Annabel Massey (counsel) in Global Markets; Hubert Blanc-Jouvan (partner) in Regulatory; and Solène Guyon (senior associate) and Lucas Halimi (associate) in tax.
